Zejing Wang

Trials

Studies that name Zejing Wang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:57 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT07566156 · Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

  Astellas Pharma Global Development, Inc. · recruiting · Urothelial Cancer, Urinary Bladder Neoplasms · study director
• Ph3
  NCT04223856 · Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

  Astellas Pharma Global Development, Inc. · active not recruiting · Urothelial Cancer · study director
• Ph1/Ph2
  NCT03310957 · Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

  Seagen Inc. · completed · Triple Negative Breast Neoplasms · study director
• Ph1
  NCT01969643 · A Safety Study of SGN-LIV1A in Breast Cancer Patients

  Seagen Inc. · completed · HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.